CAN-FITE BIOPHARMA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.64 USD | -0.55% |
|
+15.19% | +65.45% |
| Sales 2024 * | 600K 821K | Sales 2025 * | 10.6M 14.5M | Capitalization | 20.5M 28.04M |
|---|---|---|---|---|---|
| Net income 2024 * | -8M -10.94M | Net income 2025 * | - 0 | EV / Sales 2024 * | 34.2 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.93 x |
| P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 8 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.97% |
More Fundamentals
* Estimated data
More news
Latest transcript on Can-Fite BioPharma Ltd.
More press releases
| 1 day | -0.55% | ||
| 1 week | +15.19% | ||
| Current month | +41.09% | ||
| 1 month | +13.40% | ||
| 3 months | +85.71% | ||
| 6 months | +82.00% | ||
| Current year | +65.45% |
1 week
3.16
3.78
1 month
2.303.78
Current year
1.874.48
1 year
1.814.48
3 years
1.5226.00
5 years
1.5249.50
10 years
1.521 177.50
| Managers | Title | Age | Since |
|---|---|---|---|
Motti Farbstein
CEO | Chief Executive Officer | 59 | 03-07-31 |
Pnina Fishman
FOU | Founder | 74 | 94-09-10 |
Ilan Cohn
FOU | Founder | 68 | 94-09-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Abraham Sartani
BRD | Director/Board Member | 76 | 00-12-31 |
Ilan Cohn
FOU | Founder | 68 | 94-09-10 |
Pnina Fishman
FOU | Founder | 74 | 94-09-10 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-17 | 3.64 | -0.55% | 113,658 |
| 24-07-16 | 3.66 | +8.61% | 161,088 |
| 24-07-15 | 3.37 | -2.88% | 163,691 |
| 24-07-12 | 3.47 | +6.44% | 116,350 |
| 24-07-11 | 3.26 | +3.16% | 122,106 |
Delayed Quote Nyse, July 17, 2024 at 04:00 pm
More quotes
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Sector
Pharmaceuticals
Calendar
2024-08-28
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.045
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.54% | 100B | |
| +11.97% | 43.89B | |
| -11.76% | 33.24B | |
| -12.20% | 16.08B | |
| +4.00% | 14.68B | |
| -1.90% | 12.87B | |
| +178.17% | 10.55B | |
| -54.74% | 9.12B | |
| +5.24% | 8.83B |
- Stock Market
- Equities
- CANF Stock
- CANF Stock
